Neoadjuvant–Adjuvant or Adjuvant-Only Pembrolizumab in Advanced Melanoma

Patients who received 3 doses of pembrolizumab before surgery and 15 doses after surgery had significantly longer event-free survival than those who received adjuvant-only therapy with 18 doses after surgery.

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The New England journal of medicine Jg. 388; H. 9; S. 813 - 823
Hauptverfasser:	Patel, Sapna P., Othus, Megan, Chen, Yuanbin, Wright, G. Paul, Yost, Kathleen J., Hyngstrom, John R., Hu-Lieskovan, Siwen, Lao, Christopher D., Fecher, Leslie A., Truong, Thach-Giao, Eisenstein, Jennifer L., Chandra, Sunandana, Sosman, Jeffrey A., Kendra, Kari L., Wu, Richard C., Devoe, Craig E., Deutsch, Gary B., Hegde, Aparna, Khalil, Maya, Mangla, Ankit, Reese, Amy M., Ross, Merrick I., Poklepovic, Andrew S., Phan, Giao Q., Onitilo, Adedayo A., Yasar, Demet G., Powers, Benjamin C., Doolittle, Gary C., In, Gino K., Kokot, Niels, Gibney, Geoffrey T., Atkins, Michael B., Shaheen, Montaser, Warneke, James A., Ikeguchi, Alexandra, Najera, Jose E., Chmielowski, Bartosz, Crompton, Joseph G., Floyd, Justin D., Hsueh, Eddy, Margolin, Kim A., Chow, Warren A., Grossmann, Kenneth F., Dietrich, Eliana, Prieto, Victor G., Lowe, Michael C., Buchbinder, Elizabeth I., Kirkwood, John M., Korde, Larissa, Moon, James, Sharon, Elad, Sondak, Vernon K., Ribas, Antoni
Format:	Journal Article
Sprache:	Englisch
Veröffentlicht:	United States Massachusetts Medical Society 02.03.2023
Schlagworte:	Adjuvants Adjuvants, Immunologic Antineoplastic Agents, Immunological - administration & dosage Antineoplastic Agents, Immunological - adverse effects Antineoplastic Agents, Immunological - therapeutic use Biopsy Cancer therapies Chemotherapy, Adjuvant Coronaviruses COVID-19 Dermatology Disease Progression Hematology HIV Human immunodeficiency virus Humans Immunotherapy Lymphocytes Melanoma Melanoma - drug therapy Melanoma - pathology Melanoma - surgery Metastasis Monoclonal antibodies Neoadjuvant Therapy Oncology Patients Pembrolizumab Radiation therapy Review boards Skin Cancer Skin Neoplasms - drug therapy Skin Neoplasms - pathology Skin Neoplasms - surgery Surgery Surgery General Surgical outcomes Survival Targeted cancer therapy Treatments in Oncology
ISSN:	0028-4793, 1533-4406, 1533-4406
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!